KR20100015786A - 환형의 수용체-연관된 단백질(ｒａｐ) 펩티드 - Google Patents

환형의 수용체-연관된 단백질(ｒａｐ) 펩티드 Download PDF

Info

Publication number
KR20100015786A
KR20100015786A KR1020097022037A KR20097022037A KR20100015786A KR 20100015786 A KR20100015786 A KR 20100015786A KR 1020097022037 A KR1020097022037 A KR 1020097022037A KR 20097022037 A KR20097022037 A KR 20097022037A KR 20100015786 A KR20100015786 A KR 20100015786A
Authority
KR
South Korea
Prior art keywords
rap
peptide
cyclic
cyclic rap
mutation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020097022037A
Other languages
English (en)
Korean (ko)
Inventor
크리스토퍼 엠 스타
토드 씨 잰켈
Original Assignee
랩터 파마슈티컬 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 랩터 파마슈티컬 인코포레이티드 filed Critical 랩터 파마슈티컬 인코포레이티드
Publication of KR20100015786A publication Critical patent/KR20100015786A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/655—Somatostatins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020097022037A 2007-03-21 2008-03-21 환형의 수용체-연관된 단백질(ｒａｐ) 펩티드 Ceased KR20100015786A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91923807P 2007-03-21 2007-03-21
US60/919,238 2007-03-21

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020157020697A Division KR101801454B1 (ko) 2007-03-21 2008-03-21 환형의 수용체-연관된 단백질(ｒａｐ) 펩티드

Publications (1)

Publication Number Publication Date
KR20100015786A true KR20100015786A (ko) 2010-02-12

Family

ID=39591450

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020097022037A Ceased KR20100015786A (ko) 2007-03-21 2008-03-21 환형의 수용체-연관된 단백질(ｒａｐ) 펩티드
KR1020157020697A Expired - Fee Related KR101801454B1 (ko) 2007-03-21 2008-03-21 환형의 수용체-연관된 단백질(ｒａｐ) 펩티드

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020157020697A Expired - Fee Related KR101801454B1 (ko) 2007-03-21 2008-03-21 환형의 수용체-연관된 단백질(ｒａｐ) 펩티드

Country Status (10)

Country Link
US (1) US8440629B2 (enExample)
EP (1) EP2132224B1 (enExample)
JP (1) JP2010524849A (enExample)
KR (2) KR20100015786A (enExample)
CN (1) CN101861334A (enExample)
AT (1) ATE539089T1 (enExample)
BR (1) BRPI0809234A2 (enExample)
CA (1) CA2681522A1 (enExample)
MX (1) MX2009010148A (enExample)
WO (1) WO2008116171A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4903036B2 (ja) 2003-01-06 2012-03-21 アンジオケム・インコーポレーテッド 血液脳関門を通過する担体としてのアプロチニンおよび類似体
US9365634B2 (en) 2007-05-29 2016-06-14 Angiochem Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
WO2009127072A1 (en) 2008-04-18 2009-10-22 Angiochem Inc. Pharmaceutical compositions of paclitaxel, paclitaxel analogs or paclitaxel conjugates and related methods of preparation and use
US8129341B2 (en) * 2008-08-25 2012-03-06 New York University Methods for treating diabetic wounds
WO2010043047A1 (en) 2008-10-15 2010-04-22 Angiochem Inc. Conjugates of glp-1 agonists and uses thereof
CA2740317A1 (en) 2008-10-15 2010-04-22 Angiochem Inc. Etoposide and doxorubicin conjugates for drug delivery
US9914754B2 (en) 2008-12-05 2018-03-13 Angiochem Inc. Conjugates of neurotensin or neurotensin analogs and uses thereof
AU2009327267A1 (en) 2008-12-17 2011-07-14 Angiochem, Inc. Membrane type-1 matrix metalloprotein inhibitors and uses thereof
EP2416763A4 (en) * 2009-04-06 2015-05-06 Mayo Foundation PROCESS AND MATERIALS FOR THE RELEASE OF MOLECULES
ES2729261T3 (es) 2009-04-20 2019-10-31 Angiochem Inc Tratamiento del cáncer de ovario utilizando un agente anticancerígeno conjugado con un análogo de Angiopep-2
WO2011000095A1 (en) 2009-07-02 2011-01-06 Angiochem Inc. Multimeric peptide conjugates and uses thereof
WO2011094536A1 (en) 2010-01-28 2011-08-04 Raptor Pharmaceuticalls Inc. Method for treating liver disorders with receptor associated protein ( irp) peptide-fucosidase inhibitor conjugates
EP4056193A1 (en) 2010-06-17 2022-09-14 New York University Therapeutic and cosmetic uses and applications of calreticulin
US8956859B1 (en) 2010-08-13 2015-02-17 Aviex Technologies Llc Compositions and methods for determining successful immunization by one or more vaccines
GB201220474D0 (en) * 2012-11-14 2012-12-26 Sagetis Biotech Sl Polypeptides
AU2014312190A1 (en) 2013-08-28 2016-02-18 Bioasis Technologies Inc. CNS-targeted conjugates of antibodies
EP3259280A4 (en) * 2015-02-20 2018-07-18 The Regents of The University of California Methods and compositions for treating glaucoma
EP3307326B9 (en) 2015-06-15 2021-02-24 Angiochem Inc. Methods for the treatment of leptomeningeal carcinomatosis
CN109422801B (zh) * 2017-08-31 2022-07-08 复旦大学 多功能靶向多肽rap及其在制备肿瘤靶向递送系统中的用途
MX2020005424A (es) * 2017-11-29 2020-12-03 Univ Texas Composiciones y metodos para terapia contra el cancer.
US12305171B2 (en) 2018-12-27 2025-05-20 Bioaffinity Technologies, Inc. Compositions and methods for treating cancer
CN113508175B (zh) * 2018-12-27 2025-08-19 生物阿非尼提科技公司 用于治疗癌症的组合物和方法
US11572394B2 (en) * 2020-02-16 2023-02-07 Pasteur Institute Of Iran Peptides for targeting LRP6-overexpressed cells
CA3128035A1 (en) 2020-08-13 2022-02-13 Bioasis Technologies, Inc. Combination therapies for delivery across the blood brain barrier
CN116286380A (zh) * 2021-12-21 2023-06-23 暨南大学 环五肽类化合物及其在α-糖苷酶抑制剂类降糖药物或预防保健品中的应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4394448A (en) * 1978-02-24 1983-07-19 Szoka Jr Francis C Method of inserting DNA into living cells
IT1122765B (it) * 1978-11-06 1986-04-23 Srm Hydromekanik Ab Frizione a dischi multipli
US4391904A (en) 1979-12-26 1983-07-05 Syva Company Test strip kits in immunoassays and compositions therein
US5186941A (en) * 1983-05-06 1993-02-16 Vestar, Inc. Vesicle formulation for the controlled release of therapeutic agents
US6048729A (en) * 1987-05-01 2000-04-11 Transkaryotic Therapies, Inc. In vivo protein production and delivery system for gene therapy
US6063630A (en) * 1991-11-05 2000-05-16 Transkaryotic Therapies, Inc. Targeted introduction of DNA into primary or secondary cells and their use for gene therapy
US6238908B1 (en) * 1995-06-07 2001-05-29 Aastrom Biosciences, Inc. Apparatus and method for maintaining and growth biological cells
DE69733132D1 (de) * 1996-01-16 2005-06-02 Ronald J Sokol Verwendung von antioxidantien zur behandlung cholestatischer lebererkrankungen
TW492882B (en) * 1997-11-28 2002-07-01 Caleb Pharmaceuticals Inc Cholinergic antagonist plaster composition
US6585971B1 (en) * 1999-11-12 2003-07-01 Harbor-Ucla Research And Education Institute Recombinant α-L-iduronidase, methods for producing and purifying the same and methods for treating disease caused by deficiencies thereof
US6569661B1 (en) * 1999-11-12 2003-05-27 Biomarin Pharmaceutical Inc. Recombinant α-L-iduronidase, methods for producing and purifying the same and methods for treating diseases caused by deficiencies thereof
US6426208B1 (en) * 1999-11-12 2002-07-30 Harbor-Ucla Research And Education Institute Recombinant α-L-iduronidase, methods for producing and purifying the same and methods for treating diseases caused by deficiencies thereof
US6261595B1 (en) * 2000-02-29 2001-07-17 Zars, Inc. Transdermal drug patch with attached pocket for controlled heating device
US6596762B2 (en) * 2001-05-17 2003-07-22 The Regents Of The University Of Colorado Antioxidant compositions and use for treatment of hepatic steatosis and steatohepatitis
US7485314B2 (en) * 2002-05-06 2009-02-03 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Induction of antigen specific immunologic tolerance
CA2525236C (en) * 2003-06-20 2015-03-24 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
US8877714B2 (en) * 2005-06-14 2014-11-04 Raptor Pharmaceutical Inc. Compositions comprising receptor-associated protein (RAP) variants specific for LRP2 and uses thereof
CN101594878A (zh) * 2006-09-18 2009-12-02 雷普特药品公司 通过给予受体相关蛋白（rap）-缀合物对肝病症的治疗

Also Published As

Publication number Publication date
US8440629B2 (en) 2013-05-14
JP2010524849A (ja) 2010-07-22
EP2132224A1 (en) 2009-12-16
CA2681522A1 (en) 2008-09-25
KR20150104584A (ko) 2015-09-15
BRPI0809234A2 (pt) 2014-09-02
MX2009010148A (es) 2009-12-01
KR101801454B1 (ko) 2017-11-24
HK1139162A1 (en) 2010-09-10
EP2132224B1 (en) 2011-12-28
US20100210517A1 (en) 2010-08-19
CN101861334A (zh) 2010-10-13
WO2008116171A1 (en) 2008-09-25
ATE539089T1 (de) 2012-01-15

Similar Documents

Publication Publication Date Title
KR101801454B1 (ko) 환형의 수용체-연관된 단백질(ｒａｐ) 펩티드
US9879064B2 (en) Compositions comprising receptor-associated protein (RAP) variants specific for CR-containing proteins and uses thereof
CA2450073C (en) Compositions and methods for modulating blood-brain barrier transport
JP5705118B2 (ja) 薬物送達のためのエトポシドおよびドキソルビシン複合体
US20090269346A1 (en) Compositions Comprising Receptor-Associated Protein (RAP) Variants Specific for LRP2 and Uses Thereof
JP2010503710A (ja) 受容体関連タンパク質（ｒａｐ）結合体の投与による肝障害の処置
AU2002322720A1 (en) Compositions and methods for modulating blood-brain barrier transport
JP2011504888A (ja) Ｎｃａｍ由来の新規ペプチド（ｆｇｌ）
HK1139162B (en) Cyclic receptor-associated protein (rap) peptides
HK1140686B (en) Compositions for blood-brain barrier transport

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20091021

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20130320

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20141027

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20150528

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20141027

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20150629

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20150528

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Appeal identifier: 2015101003745

Request date: 20150629

A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20150729

J301 Trial decision

Free format text: TRIAL NUMBER: 2015101003745; TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20150629

Effective date: 20180402

PJ1301 Trial decision

Patent event code: PJ13011S01D

Patent event date: 20180402

Comment text: Trial Decision on Objection to Decision on Refusal

Appeal kind category: Appeal against decision to decline refusal

Request date: 20150629

Decision date: 20180402

Appeal identifier: 2015101003745

PS0901 Examination by remand of revocation
S901 Examination by remand of revocation
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20180411

Patent event code: PE09021S01D

PS0601 Decision to reject again after remand of revocation

Patent event date: 20180903

Comment text: Decision to Refuse Application

Patent event code: PS06013S01D

Patent event date: 20180411

Comment text: Notification of reason for refusal

Patent event code: PS06012S01I

Patent event date: 20180402

Comment text: Notice of Trial Decision (Remand of Revocation)

Patent event code: PS06011S01I

Patent event date: 20141027

Comment text: Notification of reason for refusal

Patent event code: PS06012S01I

S601 Decision to reject again after remand of revocation